PCM
HAE icon

Portolan Capital Management’s Haemonetics HAE Stock Holding History

Portolan Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-26,747
Closed -$2.4M – 148
2020
Q2 		$2.4M Buy
26,747
+625
+2% +$63.1K 0.27% 108
2020
Q1 		$2.6M Buy
+26,122
New +$2.83M 0.39% 75

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Portolan Capital Management's HAE Position: Q3 2020 in Review

Portolan Capital Management sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 26,747 shares — an estimated $2.4M sold.

Portolan Capital Management first reported a position in HAE in Q1 2020 and held it in 2 quarters. The position peaked at $2.6M in Q1 2020. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

  • Portolan Capital Management reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
  • Portolan Capital Management sold 26,747 Haemonetics shares in Q3 2020, an estimated $2.4M.
  • Portolan Capital Management first reported a position in Haemonetics in Q1 2020 and held it in 2 quarters.
  • Portolan Capital Management's Haemonetics position peaked at $2.6M in Q1 2020.
  • 268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on Portolan Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.